



## OncoPrint™ Cell-Free Nucleic Acid Assays

### ONCOMINE PAN-CANCER CELL-FREE TOTAL NUCLEIC ACID ASSAY

Hotspot Genes					Tumor Suppressor Genes	CNV Genes		Gene Fusions	
<i>AKT1</i>	<i>EGFR</i>	<i>FLT3</i>	<i>KRAS</i>	<i>PDGFRA</i>	<i>APC</i>	<i>CCND1</i>	<i>ERBB2</i>	<i>ALK</i>	<i>FGFR3</i>
<i>ALK</i>	<i>ERBB2</i>	<i>GNA11</i>	<i>MAP2K1</i>	<i>PIK3CA</i>	<i>FBXW7</i>	<i>CCND2</i>	<i>FGFR1</i>	<i>BRAF</i>	<i>MET</i>
<i>AR</i>	<i>ERBB3</i>	<i>GNAQ</i>	<i>MAP2K2</i>	<i>RAF1</i>	<i>PTEN</i>	<i>CCND3</i>	<i>FGFR2</i>	<i>ERG</i>	<i>NTRK1</i>
<i>ARAF</i>	<i>ESR1</i>	<i>GNAS</i>	<i>MET</i>	<i>RET</i>	<i>TP53</i>	<i>CDK4</i>	<i>FGFR3</i>	<i>ETV1</i>	<i>NTRK3</i>
<i>BRAF</i>	<i>FGFR1</i>	<i>HRAS</i>	<i>MTOR</i>	<i>ROS1</i>		<i>CDK6</i>	<i>MET</i>	<i>FGFR1</i>	<i>RET</i>
<i>CHEK2</i>	<i>FGFR2</i>	<i>IDH1</i>	<i>NRAS</i>	<i>SF3B1</i>		<i>EGFR</i>	<i>MYC</i>	<i>FGFR2</i>	<i>ROS1</i>
<i>CTNNB1</i>	<i>FGFR3</i>	<i>IDH2</i>	<i>NTRK1</i>	<i>SMAD4</i>					
<i>DDR2</i>	<i>FGFR4</i>	<i>KIT</i>	<i>NTRK3</i>	<i>SMO</i>					
<ul style="list-style-type: none"> <li>• 52 genes</li> <li>• Single library from DNA and RNA</li> </ul>		<ul style="list-style-type: none"> <li>• 272 amplicons</li> <li>• &gt;900 hotspots and indels</li> </ul>		<ul style="list-style-type: none"> <li>• Extended coverage of <i>TP53</i></li> <li>• 96 fusions</li> </ul>		<ul style="list-style-type: none"> <li>• 12 CNVs</li> <li>• <i>MET</i> exon 14 skipping</li> </ul>			

### ONCOMINE (CANCER-SPECIFIC) CELL-FREE NUCLEIC ACID ASSAYS

Lung cfDNA Assay	Lung cfTNA Assay	Breast cfDNA Assay	Breast cfDNA v2 Assay	Colon cfDNA Assay
<i>ALK</i>	<i>ALK</i>	<i>AKT1</i>	<i>AKT1</i>	<i>AKT1</i>
<i>BRAF</i>	<i>BRAF</i>	<i>EGFR</i>	<i>EGFR</i>	<i>APC</i>
<i>EGFR</i>	<i>EGFR</i>	<i>ERBB2</i>	<i>ERBB2</i>	<i>ERBB2</i>
<i>ERBB2</i>	<i>ERBB2</i>	<i>ERBB3</i>	<i>ERBB3</i>	<i>ERBB3</i>
<i>KRAS</i>	<i>KRAS</i>	<i>ESR1</i>	<i>ESR1</i>	<i>ESR1</i>
<i>MAP2K1</i>	<i>MAP2K1</i>			
<i>MET</i>	<i>MET</i>	<i>FBXW7</i>	<i>FBXW7</i>	<i>ERBB2</i>
<i>NRAS</i>	<i>NRAS</i>	<i>KRAS</i>	<i>KRAS</i>	<i>FBXW7</i>
<i>PIK3CA</i>	<i>PIK3CA</i>	<i>PIK3CA</i>	<i>PIK3CA</i>	<i>NRAS</i>
<i>ROS1</i>	<b><i>RET</i></b>	<i>SF3B1</i>	<i>SF3B1</i>	<i>PIK3CA</i>
<i>TP53</i>	<i>ROS1</i>	<i>TP53</i>	<i>TP53</i>	<i>SMAD4</i>
	<i>TP53</i>			<i>TP53</i>
				<i>MAP2K1</i>
<ul style="list-style-type: none"> <li>• 11 genes</li> <li>• DNA only</li> <li>• 35 amplicons</li> <li>• 169 hotspots and indels</li> </ul>	<ul style="list-style-type: none"> <li>• 12 genes</li> <li>• Single library from DNA and RNA</li> <li>• 58 amplicons</li> <li>• &gt;169 hotspots and indels</li> <li>• 49 fusions: <i>ALK</i>, <i>RET</i>, <i>ROS1</i></li> <li>• CNV: <i>MET</i></li> <li>• <i>MET</i> exon 14 skipping (3)</li> </ul>	<ul style="list-style-type: none"> <li>• 10 genes</li> <li>• DNA only</li> <li>• 26 amplicons</li> <li>• 152 hotspots and indels</li> </ul>	<ul style="list-style-type: none"> <li>• 12 genes</li> <li>• Single library to detect SNVs and CNVs</li> <li>• 76 amplicons</li> <li>• &gt;152 hotspots and indels</li> <li>• CNVs: <i>CCND1</i>, <i>ERBB2</i>, <i>FGFR1</i></li> <li>• More complete coverage of <i>TP53</i></li> </ul>	<ul style="list-style-type: none"> <li>• 14 genes</li> <li>• DNA only</li> <li>• 49 amplicons</li> <li>• 236 hotspots and indels</li> </ul>

Contact us to learn how Biodesix can support your program: [bizdev@biodesix.com](mailto:bizdev@biodesix.com)

#### About Biodesix

Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ and EarlyCDT Lung® nodule tests, evaluate the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit [www.biodesix.com](http://www.biodesix.com).